Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis
出版年份 2019 全文链接
标题
Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis
作者
关键词
Hypertension, Diabetes, Sodium-glucose transporter
出版物
CURRENT HYPERTENSION REPORTS
Volume 21, Issue 2, Pages -
出版商
Springer Nature
发表日期
2019-02-12
DOI
10.1007/s11906-019-0920-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition
- (2018) Kazuomi Kario et al. Journal of Clinical Hypertension
- Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
- (2018) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
- (2018) Christopher S. Wilcox et al. Journal of the American Heart Association
- SGLT2 Inhibitors and Mechanisms of Hypertension
- (2018) Alexandros Briasoulis et al. Current Cardiology Reports
- Salt-Responsive Metabolite, β-Hydroxybutyrate, Attenuates Hypertension
- (2018) Saroj Chakraborty et al. Cell Reports
- The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus
- (2017) Jens Jordan et al. Journal of the American Society of Hypertension
- Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis
- (2017) William L. Baker et al. Journal of the American Heart Association
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- 8. Pharmacologic Approaches to Glycemic Treatment
- (2016) DIABETES CARE
- Blood pressure goals, variability and SGLT2 blockade in CKD
- (2016) Debbie L. Cohen et al. Nature Reviews Nephrology
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes
- (2016) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels
- (2015) C. D. Sjöström et al. DIABETES OBESITY & METABOLISM
- Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
- (2015) William T. Cefalu et al. DIABETOLOGIA
- Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
- (2014) Hala Yamout et al. AMERICAN JOURNAL OF NEPHROLOGY
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
- (2014) Matthew R. Weir et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
- (2014) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Thiazide and Loop Diuretics
- (2011) Domenic A. Sica et al. Journal of Clinical Hypertension
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now